Get the Daily Brief
Latest Biotech News
Neuro‑immunology gets a $101M lift: startups build neural‑immune modality stacks
Nilo Therapeutics launched with a $101 million Series A to translate neuro‑immunology discoveries into therapies that modulate brain‑body circuits to restore immune homeostasis. Backers include...
VISTA emerges as checkpoint target: TRIM25 link boosts immunotherapy
Multiple preclinical studies strengthened VISTA’s candidacy as an immune‑checkpoint target. One paper shows that loss of TRIM25 enhances anti‑tumor immunity by modulating VISTA pathways in T...
Ultra‑mild methylation sequencing... cancer epigenetics gets gentler, deeper tools
The University of Chicago introduced Ultra‑Mild Bisulfite Sequencing (UMBS‑seq), a new method that preserves DNA while delivering accurate, genome‑wide methylation profiles—addressing major...
Gene therapy for bladder cancer surges — Engene posts pivotal Phase II
Engene released additional pivotal‑cohort data for detalimogene voraplasmid, a nonviral gene therapy for high‑risk, BCG‑unresponsive non‑muscle‑invasive bladder cancer with carcinoma‑in‑situ. The...
AI meets tissue biology: BostonGene‑Kyoto deal and Dyno’s AI capsids
BostonGene agreed with Kyoto University to apply its AI‑powered molecular platform to identify biomarkers and immune pathways in esophageal squamous cell carcinoma, combining genomic and...
Novartis to file for approval after Phase 3 win – ganaplacide combo meets WHO cure target
Novartis reported Phase 3 results showing its ganaplacide-based combination therapy (GanLum) achieved cure rates that exceed the World Health Organization’s 95% threshold in trials across...
Single-dose malaria cocktail: Four‑drug shot matches standard multi‑day regimen in Gabon
A Phase 3 trial in Gabon presented at ASTMH found that a single‑dose regimen combining four existing antimalarials matched the effectiveness of conventional multi‑day therapy. Investigators...
FDA unveils new regulatory pathway: faster routes for personalized rare‑disease therapies
Top FDA officials sketched a new regulatory approach designed to expedite bespoke therapies for patients with ultra‑rare conditions. Agency leaders outlined a 'plausible mechanism' pathway that...
Nilo launches with $101M — aims to harness neural circuits to reset immunity
Nilo Therapeutics launched out of academic labs with a $101 million Series A to translate neuro‑immunology discoveries into therapies for autoimmune and inflammatory diseases. The New York‑based...
CRISPR’s mixed week: breakthrough cholesterol data shadowed by trial death
The CRISPR field saw divergent news: a promising in‑vivo cholesterol editing readout was published days after Intellia reported a fatality in its MAGNITUDE Phase III program and an FDA...
GLP‑1 drugs linked to halved mortality in colon cancer cohort
A multi‑site UC Health analysis of more than 6,800 colon cancer patients found those prescribed GLP‑1 receptor agonists had substantially lower five‑year mortality versus non‑users, with adjusted...
UniQure gene therapy shows large slowing of Huntington’s in early trial
UniQure reported that its intracranial AAV‑delivered microRNA therapy AMT‑130 produced a 75% slowing of Huntington’s disease progression versus historical controls at three years in a Phase 1/2...
Nucleai and BostonGene expand AI spatial‑biology efforts with academic partners
Two AI‑driven collaborations advanced tissue biomarker discovery: Nucleai partnered with the University of Glasgow to develop multimodal spatial biomarkers for colorectal cancer and risk...
Lilly doubles down on genetic medicine: vision gene‑therapy deal and $1.2B RNAi pact
Eli Lilly expanded its genetic‑medicine footprint with two major moves: a licensing agreement with MeiraGTx for an AAV‑AIPL1 gene therapy that restored vision in pediatric LCA4 patients and a $1.2...
Beacon raises $86M — building a brain‑wave dataset to power neurology R&D
Beacon Biosignals closed an $86 million financing to scale a longitudinal brain‑wave dataset intended to accelerate drug development and diagnostics for neurological diseases. The company will...
FDA taps Pazdur: Veteran oncology chief named CDER director
The FDA on Nov. 11 installed Richard Pazdur — the agency’s longtime oncology director — as head of the Center for Drug Evaluation and Research (CDER). The appointment follows the abrupt departure...
AbbVie exits Calico: 11-year aging partnership wound down, layoffs follow
AbbVie notified staff that it will end its 11-year collaboration with Alphabet’s Calico Labs and is preparing layoffs tied to the wind‑down of joint aging projects. The partnership — which AbbVie...
Nilo launches with $101M: Neuro‑immunology startup aims to rewire inflammation
Nilo Therapeutics launched from New York with $101 million in Series A backing to translate neuro‑immunology discoveries into therapies for autoimmune and inflammatory conditions. The company was...
Lilly licenses MeiraGTx gene therapy: $75M upfront for AAV‑AIPL1 in childhood blindness
Eli Lilly agreed to acquire exclusive worldwide rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4), paying $75 million up front and up to $400 million in...
EnGene/Engene posts pivotal bladder data — shares surge on Phase II results
Two related updates from EnGene/Engene reinforced plans for a biologics license application in high‑risk, BCG‑unresponsive non‑muscle‑invasive bladder cancer. The companies reported additional...